Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clobetasol ViaFoam 0: CNCT began a Phase III trial

CNCT expects to submit an NDA in the first half

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE